Spikevax from Moderna: how the mRNA COVID-19 vaccine fits into 2026 protection

Spikevax, the COVID-19 vaccine from Moderna, is an mRNA-based vaccine designed to help the immune system recognize the SARS-CoV-2 virus, according to Moderna product information and US Food and Drug Administration documents (Moderna, 01/2024; FDA, 01/2024).

Updated: 05/19/2026 | Reading time: approx. 9 minutes

By the AD HOC NEWS editorial team - specialized in product-led market coverage.

What Spikevax Is and How It Works

Spikevax is a messenger RNA vaccine that encodes a piece of the spike protein from the SARS-CoV-2 virus, as described in the US prescribing information and the original emergency use documents (FDA, 01/2024; Moderna, 02/2024).

The mRNA in Spikevax is packaged in lipid nanoparticles. After injection into a muscle, cells take up the mRNA and use it as instructions to make a version of the spike protein, according to Moderna and the Centers for Disease Control and Prevention (CDC, 12/2023; Moderna, 11/2023).

This process triggers the immune system to generate antibodies and cellular responses that recognize the spike protein. The mRNA from Spikevax does not enter the cell nucleus and is broken down by normal cellular processes, as explained by CDC and FDA educational materials (CDC, 10/2023; FDA, 09/2023).

Why Spikevax Matters for Consumers and Industry

For US residents, Spikevax is one of the mRNA COVID-19 vaccines that have been authorized or approved to help reduce the risk of symptomatic and severe COVID-19, according to FDA and CDC vaccination guidance (FDA, 09/2023; CDC, 09/2023).

Public health agencies emphasize that vaccination is one tool, alongside ventilation, masking in some settings and testing, to help lower the risk of serious outcomes from COVID-19, especially for older adults and people with certain medical conditions (CDC, 11/2023; WHO, 10/2023).

For healthcare providers and employers, Spikevax is part of a broader toolkit to manage respiratory virus seasons. US guidance on vaccination for workers and healthcare settings highlights the role of COVID-19 vaccines in protecting critical infrastructure and healthcare capacity (OSHA, 10/2023; CDC, 09/2023).

Spikevax in the US and Global Market

In the United States, Spikevax is supplied as an mRNA COVID-19 vaccine option alongside other formulations, and the CDC offers recommendations on who should receive updated doses during each season (CDC, 09/2023; FDA, 01/2024).

Outside the US, regulators such as the European Medicines Agency and Health Canada have also authorized Spikevax or related Moderna COVID-19 vaccines, with local product information and schedules that reflect regional policies (EMA, 10/2023; Health Canada, 11/2023).

Public communication from health agencies underlines that product names, dose schedules and age indications can change as updated formulations are authorized, so they direct patients and clinicians to current local guidance for details (CDC, 01/2024; EMA, 09/2023).

• mRNA platform encoding SARS-CoV-2 spike protein
• Intramuscular injection, commonly in the upper arm
• Formulations adjusted over time to match variants
• Used alongside non-pharmaceutical measures in public health

Frequently Asked Questions About Spikevax

How does Spikevax differ from traditional vaccines?
Spikevax uses messenger RNA that instructs cells to produce a viral spike protein for the immune system to recognize, instead of using inactivated virus or protein subunits (CDC, 10/2023; Moderna, 11/2023).

Can Spikevax change a person in genetic terms?
Health agencies state that mRNA from vaccines does not enter the cell nucleus and does not interact with DNA, and it is broken down shortly after vaccination (CDC, 10/2023; FDA, 09/2023).

Where can US residents find current guidance on Spikevax?
Current recommendations on who should receive Spikevax or other COVID-19 vaccines in the US are maintained by the CDC and FDA on their official websites (CDC, 09/2023; FDA, 01/2024).

Spikevax is developed and marketed by Moderna, a biotechnology company that focuses on mRNA-based medicines, including vaccines and investigational therapeutics (Moderna, 11/2023; SEC, 02/2024).

Moderna, the company behind Spikevax, is listed on the Nasdaq stock market in the United States under the ticker MRNA, and its shares are associated with the ISIN US60770K1079 (Nasdaq, 02/2024; SEC, 02/2024).

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.